APA (7th ed.) Citation

Schmoll, H., Lindner, L. H., Reichardt, P., Heißner, K., Kopp, H., Kessler, T., . . . Stein, A. (2021). Efficacy of pazopanib with or without gemcitabine in patients with anthracycline- and/or ifosfamide-refractory soft tissue sarcoma: Final results of the PAPAGEMO phase 2 randomized clinical trial. JAMA oncology, 7(2), . https://doi.org/10.1001/jamaoncol.2020.6564

Chicago Style (17th ed.) Citation

Schmoll, Hans-Joachim, et al. "Efficacy of Pazopanib with or Without Gemcitabine in Patients with Anthracycline- And/or Ifosfamide-refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial." JAMA Oncology 7, no. 2 (2021). https://doi.org/10.1001/jamaoncol.2020.6564.

MLA (9th ed.) Citation

Schmoll, Hans-Joachim, et al. "Efficacy of Pazopanib with or Without Gemcitabine in Patients with Anthracycline- And/or Ifosfamide-refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial." JAMA Oncology, vol. 7, no. 2, 2021, https://doi.org/10.1001/jamaoncol.2020.6564.